1. Long-Acting Agents in Severe COPD

2. Long-Acting Agents in Severe COPD

3. Program

4. Part 1: Choosing Single vs Dual Bronchodilator Therapy

5. Patient Case

6. GOLD COPD Multidimensional Assessment Approach

7. Standardized Tools: CAT and mMRC Dyspnea Scale

8. GOLD Therapeutic Recommendations

9. LAMA and LABA Result in Similar QoL Improvement

10. Patient Case

11. Relationship Between FEV1 and SGRQ

12. Symptomatic Response to Dual Bronchodilation Is Dependent on Baseline Symptom Burden

13. Meta-Analysis Favors Dual Bronchodilators Over Mono Components to Improve Exercise Capacity

14. Part 2: Choosing Dual vs Triple Bronchodilator Therapy

15. Patient Case

16. GOLD Therapeutic Recommendations

17. LAMA Reduces Exacerbations Compared With a LABA

18. FLAME: Probability of a First Mild, Moderate, or Severe Exacerbation on Treatment

19. IMPACT: ICS/LABA Decreased the Rate of On-Treatment Moderate/Severe Exacerbations vs LAMA/LABA

20. Inclusion/Exclusion Criteria for IMPACT

21. LABA/LAMA/ICS Decreases Exacerbations Compared With LAMA and LAMA/LABA

22. IMPACT: LABA/LAMA/ICS Reduces Moderate/Severe Exacerbations vs Individual Dual Combinations in Same Device

23. Patient Case

24. ICS Is Associated With Improved All-Cause Mortality (On-Treatment Data) but Increased Pneumonia in IMPACT

25. Risk Factors Associated With CXR-Confirmed Pneumonia in Patients With COPD Treated With ICS

26. Part 3: Does Eosinophil Count Influence Treatment Decision?

27. Patient Case

28. Patient Case

29. FLAME Subgroup Analysis by Circulating Eosinophils

30. Eosinophil Count Determines Response to BUD-FM as Compared With FM Alone

31. IMPACT: Rate of Moderate/Severe Exacerbations in the Non-ICS-Containing Arm (UMEC/VI) Increased With Baseline Blood Eosinophil Count

32. Mepolizumab in Eosinophilic COPD

33. Part 4: When Bronchodilation Is Not Sufficient -- Role of Oral Agents

34. Patient Case

35. GOLD Therapeutic Recommendations

36. Roflumilast Response Is Particularly Evident in COPD Patients With Distinct Phenotypes

37. Predictors of COPD Exacerbation Reduction in Response to Daily Azithromycin Therapy

38. Abbreviations

39. Abbreviations (cont)